Dr. Milstein is currently the Scientific Officer at Ception Therapeutics, Inc. Ception’s lead program is a monoclonal antibody, currently in clinical trials, for the treatment Eosinophilic Esophagisitis and Asthma. Dr. Milstein is responsible for technical planning and oversight of the drug discovery arm of the company. From 2001-2006, Dr. Milstein was the founder/CEO of Fulcrum Pharmaceuticals (later merged with Ception), a drug discovery, drug design company. Fulcrum’s technology designed an oral MRSA compound with a novel mechanism of action and a family of TNFR1 inhibitors for the treatment of rheumatoid arthritis. Dr. Milstein received his Ph.D. in biochemistry at New York University. He completed his Post-Doc Fellowship at the Sloan-Kettering Cancer Institute in 1982.

Company Profile (History) | Senior Management Team | Board of Directors | Scientific Advisory Board
Bijan Almassian, Ph.D. | Marc A. Silver, M.B.A. | Yoshitomo Hamuro, Ph.D. | Sam Milstein, Ph.D